Engineering T cells for immunotherapy of primary human hepatocellular carcinoma

作     者：Leidy DCaraballo Galva Lun Cai Yanxia Shao Yukai He Leidy D.Caraballo Galva;Lun Cai;Yanxia Shao;Yukai He

作者机构：Georgia Cancer Center.Medical College of GeorgiaAugusta University.AugustaGA.30912USA Department of Medicine.Medical College of GeorgiaAugusta UniversityAugustaGA30912USA 

出 版 物：《Journal of Genetics and Genomics》 (遗传学报（英文版）)

年 卷 期：2020年第47卷第1期

页      面：1-15页

核心收录：

学科分类：0710[理学-生物学] 1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100214[医学-肿瘤学] 10[医学] 

基　　金：NIH/NCI grants(R01CA168912 and R01CA235159) Augusta University intramural grant 

主　　题：Immunotherapy Hepatocellular carcinoma T cell receptor Chimeric antigen receptor T cell engineering Gene transfer 

摘      要：Liver cancers, majority of which are primary hepatocellular carcinoma(HCC), continue to be on the rise in the world. Furthermore, due to the lack of effective treatments, liver cancer ranks the 4th most common cause of male cancer deaths. Novel therapies are urgently needed. Over the last few years,immunotherapies, especially the checkpoint blockades and adoptive cell therapies of engineered T cells,have demonstrated a great potential for treating malignant tumors including HCC. In this review, we summarize the current ongoing research of antigen-specific immunotherapies including cancer vaccines and adoptive cell therapies for HCC. We briefly discuss the HCC cancer vaccine and then focus on the antigen-specific T cells genetically engineered with the T cell receptor genes(TCRTs) and the chimeric antigen receptor genes(CARTs). We first review the current options of TCRTs and CARTs immunotherapies for HCC, and then analyze the factors and parameters that may help to improve the design of TCRTs and CARTs to enhance their antitumor efficacy and safety. Our goals are to render readers a panoramic view of the current stand of HCC immunotherapies and provide some strategies to design better TCRTs and CARTs to achieve more effective and durable antitumor effects.